Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer

British Journal of Cancer

Volumn 113, Issue 6, 2015, Pages 872-877

  Stein, Alexander ^a   Atanackovic, Djordje ^a   Hildebrandt, Bert ^b   Stübs, Patrick ^c   Brugger, Wolfram ^d   Hapke, Gunnar ^e   Steffens, Claus Christoph ^f   Illerhaus, Gerald ^g   Bluemner, Ernst ^h   Stöhlmacher, Jan ⁱ   Bokemeyer, Carsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^d SCHWARZWALD BAAR KLINIKUM   (Germany)

^e Marienkrankenhaus   (Germany)

^f Onkologie Klinik Dr Hancken   (Germany)

^g KLINIKUM STUTTGART   (Germany)

^h Ecron Acunova GmbH   (Germany)

ⁱ Tumorgenetik Bonn   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; COLONY STIMULATING FACTOR; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; LEUKOPENIA; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THERAPY DELAY; THROMBOCYTE COUNT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VOMITING; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; GENETICS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MORTALITY; ONCOGENE RAS; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; GENES, RAS; HUMANS; INDUCTION CHEMOTHERAPY; LEUCOVORIN; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SEVERITY OF ILLNESS INDEX;

EID: 84941875701     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.299     Document Type: Article

References (20)

1. Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M (2011) Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist 16(11): 1557-1564.
2. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11): 1023-1034.
3. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31): 4697-4705.
4. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25(13): 1670-1676.
5. Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A (2013) FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 24(8): 2062-2067.
6. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ (2011) Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 17(17): 5783-5792.
7. Gruenberger T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R (2015) Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 26(4): 702-708.
8. Hansen TF, Christensen R, Andersen RF, Garm Spindler KL, Johnsson A, Jakobsen A (2012) The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastaticcolorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis 27(6): 715-720.
9. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Muller S, Link H, Niederle N, Rost A, Hoffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15(10): 1065-1075.
10. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31(9): 1219-1230.
11. Loupakis F, Cremolini C, Antoniotti C, Lonardi S, Ronzoni M (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. J Clin Oncol 33(15 Suppl): abstr 3510.
12. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371(17): 1609-1618.
13. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ (2013) Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One 8(7): e66774.
14. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E (2014) European cancer mortality predictions for the year 2014. Ann Oncol 25(8): 1650-1656.
15. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A (2010) Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 11(9): 845-852.
16. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis C, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94(6): 798-805.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216.
18. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. on behalf of the EGWG (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 25(Suppl 3): iii1-iii9.
19. Venook A, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney M (2014) CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32(5 suppl): abtsr LBA3.
20. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quenet F, Portier G, Nordlinger B (2008) Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 62(2): 195-201.